SK9592002A3 - A method for reduction or elimination of the incidence of menopausal symptoms, method of treatment or decreasing the risk of an acquiring disease, a pharmaceutical composition and a kit - Google Patents
A method for reduction or elimination of the incidence of menopausal symptoms, method of treatment or decreasing the risk of an acquiring disease, a pharmaceutical composition and a kit Download PDFInfo
- Publication number
- SK9592002A3 SK9592002A3 SK959-2002A SK9592002A SK9592002A3 SK 9592002 A3 SK9592002 A3 SK 9592002A3 SK 9592002 A SK9592002 A SK 9592002A SK 9592002 A3 SK9592002 A3 SK 9592002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- group
- pharmaceutical composition
- estrogen
- acid
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17860100P | 2000-01-28 | 2000-01-28 | |
PCT/CA2001/000086 WO2001054699A1 (en) | 2000-01-28 | 2001-01-26 | Selective estrogen receptor modulators in combination with estrogens |
Publications (1)
Publication Number | Publication Date |
---|---|
SK9592002A3 true SK9592002A3 (en) | 2003-12-02 |
Family
ID=22653187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK959-2002A SK9592002A3 (en) | 2000-01-28 | 2001-01-26 | A method for reduction or elimination of the incidence of menopausal symptoms, method of treatment or decreasing the risk of an acquiring disease, a pharmaceutical composition and a kit |
Country Status (21)
Country | Link |
---|---|
US (3) | US20030040510A1 (ko) |
EP (1) | EP1251855A1 (ko) |
JP (1) | JP2003520817A (ko) |
KR (1) | KR20020073566A (ko) |
CN (1) | CN1400904A (ko) |
AR (1) | AR035564A1 (ko) |
AU (1) | AU2991301A (ko) |
BR (1) | BR0108107A (ko) |
CA (1) | CA2395730A1 (ko) |
CZ (1) | CZ20022401A3 (ko) |
HK (1) | HK1048761A1 (ko) |
HU (1) | HUP0204211A3 (ko) |
IL (1) | IL149990A0 (ko) |
MX (1) | MXPA02007165A (ko) |
NO (1) | NO20023484D0 (ko) |
NZ (1) | NZ534348A (ko) |
PL (1) | PL357163A1 (ko) |
RU (1) | RU2342145C2 (ko) |
SK (1) | SK9592002A3 (ko) |
WO (1) | WO2001054699A1 (ko) |
ZA (1) | ZA200205926B (ko) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7258996A (en) * | 1995-10-06 | 1997-04-28 | Arch Development Corporation | Methods and compositions for viral enhancement of cell killing |
US6358991B2 (en) * | 2000-07-06 | 2002-03-19 | American Home Products Corporation | Methods of treating neuropeptide Y-related conditions |
CA2414111A1 (en) * | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted indole compounds for increasing nitric oxide synthase activity |
US6245819B1 (en) | 2000-07-21 | 2001-06-12 | Hormos Medical Oy, Ltd. | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
IL145838A (en) * | 2000-10-16 | 2008-11-03 | Pfizer Prod Inc | Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis |
ATE376832T1 (de) * | 2001-07-06 | 2007-11-15 | Penwest Pharmaceuticals Co | Verzögert freisetzende formulierungen von oxymorphon |
IL158871A0 (en) * | 2001-07-31 | 2004-05-12 | Pfizer Prod Inc | Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
US20050080143A1 (en) * | 2001-11-29 | 2005-04-14 | Steiner Mitchell S. | Treatment of androgen-deprivation induced osteoporosis |
US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
US20040214898A1 (en) * | 2001-11-29 | 2004-10-28 | Steiner Mitchell S. | Methods for treating hot flashes |
US20060269611A1 (en) * | 2001-11-29 | 2006-11-30 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20070197664A1 (en) * | 2001-11-29 | 2007-08-23 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
TW200307553A (en) * | 2002-05-24 | 2003-12-16 | Akzo Nobel Nv | Treatment of post-menopausal complaints in breast cancer patients |
RU2317816C2 (ru) * | 2002-06-06 | 2008-02-27 | Хормос Медикал Корпорейшн | Способ ингибирования атрофии или лечения или предупреждения симптомов, родственных атрофии, у женщин |
EP1499278B1 (en) * | 2003-05-23 | 2005-06-01 | Akzo Nobel N.V. | Immediate-release pharmaceutical dosage form comprising polymorphous tibolone |
EP1713770A1 (en) * | 2004-01-29 | 2006-10-25 | Eli Lilly And Company | Selective estrogen receptor modulators |
WO2006032085A1 (en) | 2004-09-21 | 2006-03-30 | Novogen Research Pty Ltd | Substituted chroman derivatives, medicaments and use in therapy |
US8080675B2 (en) | 2004-09-21 | 2011-12-20 | Marshall Edwards, Inc. | Chroman derivatives, medicaments and use in therapy |
WO2006042409A1 (en) | 2004-10-20 | 2006-04-27 | Endorecherche, Inc. | Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women |
US20060211672A1 (en) * | 2005-02-16 | 2006-09-21 | Wyeth | Use of estrogen receptor-beta selective agonists for radiation-or chemotherapy-induced mucositis and radiation cystitis |
EP2034984A4 (en) | 2006-06-02 | 2013-03-06 | Pear Tree Women S Health Care | PROCESS FOR TREATING ATROPHIC VAGINITIS |
WO2008002490A2 (en) * | 2006-06-23 | 2008-01-03 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
WO2008101030A1 (en) * | 2007-02-13 | 2008-08-21 | The Regents Of The University Of California | Methods for amplifying steroid hormone effects |
JP5363344B2 (ja) | 2007-02-14 | 2013-12-11 | ホルモス メディカル リミテッド | 治療に有用なトリフェニルブテン誘導体の調製方法 |
US7504530B2 (en) | 2007-02-14 | 2009-03-17 | Hormos Medical Ltd. | Methods for the preparation of fispemifene from ospemifene |
US8268806B2 (en) | 2007-08-10 | 2012-09-18 | Endorecherche, Inc. | Pharmaceutical compositions |
US20140040862A1 (en) * | 2008-04-03 | 2014-02-06 | Adobe Systems Incorporated | Copying Reusable Components from a Remote Source |
AU2014201406B2 (en) * | 2009-06-16 | 2016-08-11 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
AU2016235019B2 (en) * | 2009-06-16 | 2018-06-28 | Endorecherche, Inc. | Treatment of alzheimer's disease, loss of cognition, memory loss, and dementia with sex steroid precursors in combination with selective estrogen receptor modulators |
US20100317635A1 (en) * | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
EP3106159A1 (en) | 2010-05-12 | 2016-12-21 | Radius Health, Inc. | Therapeutic regimens |
EP3205648A1 (en) * | 2010-06-10 | 2017-08-16 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
WO2011159769A2 (en) | 2010-06-17 | 2011-12-22 | Aragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
WO2012061413A2 (en) | 2010-11-01 | 2012-05-10 | Marshall Edwards, Inc. | Isoflavonoid compositions and methods for the treatment of cancer |
UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування | |
ES2885523T3 (es) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Formulaciones y terapias de reposición hormonal de combinación naturales |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
WO2013090829A1 (en) | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
JP2015505856A (ja) | 2011-12-16 | 2015-02-26 | オレマ ファーマシューティカルズ インク. | 新規のベンゾピラン化合物、その組成物および使用 |
CN102584687A (zh) * | 2011-12-30 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 作为选择性雌激素受体调节剂的乙烯衍生物 |
AU2013221478B2 (en) * | 2012-02-14 | 2017-06-01 | Repros Therapeutics Inc. | Selective estrogen receptor modulators with short half-lives and uses thereof |
CN102631677A (zh) * | 2012-04-19 | 2012-08-15 | 中国农业大学 | 一种预防和/或治疗动脉粥样硬化的药物组合物 |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
WO2014060639A1 (en) | 2012-10-19 | 2014-04-24 | Fermion Oy | A process for the preparation of ospemifene |
MX2015005160A (es) | 2012-11-02 | 2015-07-17 | Repros Therapeutics Inc | Trans-clomifeno para uso en terapia de cancer. |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
US9744177B2 (en) | 2014-03-10 | 2017-08-29 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
CA2943611A1 (en) | 2014-03-28 | 2015-10-01 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
JP2017523138A (ja) | 2014-07-29 | 2017-08-17 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 経皮クリーム |
ES2877712T3 (es) | 2015-02-02 | 2021-11-17 | Mei Pharma Inc | Terapias combinadas para su uso en el tratamiento del cáncer de mama |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
WO2018071440A1 (en) | 2016-10-11 | 2018-04-19 | Duke University | Treatment of breast cancer |
KR102557321B1 (ko) | 2017-01-05 | 2023-07-18 | 래디어스 파마슈티컬스, 인코포레이티드 | Rad1901-2hcl의 다형 형태 |
US20180207264A1 (en) * | 2017-01-23 | 2018-07-26 | Government Of The United States As Represented By The Secretary Of The Air Force | Porcine immune modulation model |
CN117771239A (zh) | 2018-04-10 | 2024-03-29 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5776923A (en) * | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
US5446061A (en) * | 1993-11-05 | 1995-08-29 | Eli Lilly And Company | Methods for lowering serum cholesterol |
US5446071A (en) * | 1994-11-18 | 1995-08-29 | Eli Lilly And Company | Methods for lowering serum cholesterol |
US5897539A (en) * | 1995-09-28 | 1999-04-27 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
DE69707189T2 (de) * | 1996-04-19 | 2002-06-20 | American Home Prod | Östrogene Verbindungen |
AR017256A1 (es) * | 1997-08-21 | 2001-09-05 | American Home Prod | Compuestos de indol sustituidos, metodo para la sintesis en fase solida de los mismos, conjuntos de combinacion para ser empleados en dicho metodo, uso delos compuestos para preparar un medicamento y composiciones farmaceuticas que los comprenden |
US7005428B1 (en) * | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
DE19916419B4 (de) * | 1999-04-08 | 2005-06-16 | Schering Ag | Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose |
AU5957500A (en) * | 1999-07-06 | 2001-01-22 | Endorecherche Inc. | Methods of treating and/or suppressing weight gain |
-
2001
- 2001-01-26 WO PCT/CA2001/000086 patent/WO2001054699A1/en active Application Filing
- 2001-01-26 KR KR1020027009728A patent/KR20020073566A/ko not_active Application Discontinuation
- 2001-01-26 HU HU0204211A patent/HUP0204211A3/hu unknown
- 2001-01-26 AU AU29913/01A patent/AU2991301A/en not_active Abandoned
- 2001-01-26 CZ CZ20022401A patent/CZ20022401A3/cs unknown
- 2001-01-26 EP EP01902194A patent/EP1251855A1/en not_active Withdrawn
- 2001-01-26 JP JP2001554683A patent/JP2003520817A/ja active Pending
- 2001-01-26 SK SK959-2002A patent/SK9592002A3/sk not_active Application Discontinuation
- 2001-01-26 BR BR0108107-1A patent/BR0108107A/pt not_active Application Discontinuation
- 2001-01-26 MX MXPA02007165A patent/MXPA02007165A/es not_active Application Discontinuation
- 2001-01-26 RU RU2002123047/14A patent/RU2342145C2/ru not_active IP Right Cessation
- 2001-01-26 CA CA002395730A patent/CA2395730A1/en not_active Abandoned
- 2001-01-26 IL IL14999001A patent/IL149990A0/xx unknown
- 2001-01-26 CN CN01804028A patent/CN1400904A/zh active Pending
- 2001-01-26 AR ARP010100372A patent/AR035564A1/es unknown
- 2001-01-26 PL PL01357163A patent/PL357163A1/xx not_active Application Discontinuation
- 2001-01-26 NZ NZ534348A patent/NZ534348A/en active IP Right Revival
- 2001-11-07 US US10/052,824 patent/US20030040510A1/en not_active Abandoned
- 2001-11-07 US US10/052,803 patent/US20020198179A1/en not_active Abandoned
-
2002
- 2002-05-09 US US10/143,894 patent/US20030065008A1/en not_active Abandoned
- 2002-07-22 NO NO20023484A patent/NO20023484D0/no not_active Application Discontinuation
- 2002-07-24 ZA ZA200005926A patent/ZA200205926B/xx unknown
-
2003
- 2003-02-06 HK HK03100850.6A patent/HK1048761A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
NO20023484L (no) | 2002-07-22 |
EP1251855A1 (en) | 2002-10-30 |
US20020198179A1 (en) | 2002-12-26 |
US20030040510A1 (en) | 2003-02-27 |
CA2395730A1 (en) | 2001-08-02 |
RU2342145C2 (ru) | 2008-12-27 |
ZA200205926B (en) | 2003-07-24 |
NZ534348A (en) | 2006-06-30 |
AR035564A1 (es) | 2004-06-16 |
HUP0204211A2 (hu) | 2003-04-28 |
US20030065008A1 (en) | 2003-04-03 |
CZ20022401A3 (cs) | 2003-10-15 |
HUP0204211A3 (en) | 2005-06-28 |
KR20020073566A (ko) | 2002-09-27 |
BR0108107A (pt) | 2003-03-11 |
WO2001054699A1 (en) | 2001-08-02 |
IL149990A0 (en) | 2002-12-01 |
HK1048761A1 (zh) | 2003-04-17 |
MXPA02007165A (es) | 2003-09-22 |
AU2991301A (en) | 2001-08-07 |
NO20023484D0 (no) | 2002-07-22 |
RU2002123047A (ru) | 2004-03-10 |
JP2003520817A (ja) | 2003-07-08 |
CN1400904A (zh) | 2003-03-05 |
PL357163A1 (en) | 2004-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK9592002A3 (en) | A method for reduction or elimination of the incidence of menopausal symptoms, method of treatment or decreasing the risk of an acquiring disease, a pharmaceutical composition and a kit | |
KR100944261B1 (ko) | 디하이드로에피안드로스테론(dhea) 또는 그 동족체와복합한 선택적인 에스트로겐 수용체 조절자 | |
JP2018203785A (ja) | 性ステロイド前駆体と選択的エストロゲン受容体モジュレーターとの組み合わせによるホットフラッシュ、血管運動症状、寝汗、アルツハイマー病、認知機能の喪失、記憶喪失及び痴呆症の治療 | |
TWI293251B (en) | Selective estrogen receptor modulators incombination with estrogens | |
AU2006201900A1 (en) | Selective estrogen receptor modulators in combination with estrogens | |
PL203438B1 (pl) | Kompozycja farmaceutyczna zawieraj aca dehydroepiandrosteron, pochodn a trifenyloetylenu i farmaceutycznie dopuszczaln a zaróbk e, zestaw i zastosowanie dehydroepiandrosteronu | |
PL203439B1 (pl) | Kompozycja farmaceutyczna zawieraj aca dehydroepiandrosteron, pochodn a indolu i farmaceutycznie dopuszczaln a zaróbk e, zestaw i zastosowanie dehydroepiandrosteronu | |
AU2014206150A1 (en) | Medical Uses of a Selective Estrogen Receptor Modulator in Combination with Sex Steroid Precursors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC9A | Refused patent application |